We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Protein Structure Revealed by Mass Spectrometry Technique

By LabMedica International staff writers
Posted on 31 May 2011
An advanced mass spectroscopy technique was used to detail the structure of a signaling protein critical to physiological processes involved in major diseases such as diabetes and cancer.

The protein, Epac2 (exchange protein directly activated by cAMP 2), is a guanine nucleotide exchange factor that regulates a wide variety of intracellular processes in response to second messenger cAMP (cyclic adenosine monophosphate).

A collaborative project was carried out by investigators at the University of Texas Medical Branch (Galveston, USA) and the University of California, San Diego (USA) to define the three-dimensional structure of Epac2 in the presence and absence of cAMP using an advanced mass spectroscopy technique known as hydrogen/deuterium exchange mass spectrometry (DXMS).

Results published in the May 20, 2011, issue of the Journal of Biological Chemistry revealed that that cAMP interacted with its two known binding sites on Epac2 in a sequential fashion and that binding of cAMP changed the shape of the protein in a very specific way. More...
This shape change was caused by a major hinge motion centered on the C- terminus of the second cAMP binding domain. This conformational change realigned the regulatory components of Epac2 away from the catalytic core, making the later available for effector binding.

"This study applied a powerful protein structural analysis approach to investigate how a chemical signal called cAMP turns on one of its protein switches, Epac2," said senior author Dr. Xiaodong Cheng, professor of pharmacology and toxicology at the University of Texas Medical Branch.

"DXMS analysis has proved to be an amazingly powerful approach, alone or in combination with other techniques, in figuring out how proteins work as molecular machines, changing their shapes – or morphing – in the normal course of their function," said contributing author Dr. Virgil Woods, professor of medicine at the University of California, San Diego. "This will be of great use in the identification and development of therapeutic drugs that target these protein motions."

Related Links:
University of Texas Medical Branch
University of California, San Diego




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.